| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
TGF-β1[1]
|
|---|---|
| ln Vitro |
The activation of TGF-β from its latent state is attributed to the interaction between the KTFR sequence from ADAMTS1 and the LSKL, Inhibitor of Thrombospondin (TSP-1) (LSKL peptide). Three salt bridges and two hydrogen bonds define a stable binding mechanism between the ADAMTS1 KTFR sequence and LSKL, an inhibitor of thrombospondin (TSP-1)[2].
|
| ln Vivo |
In male Sprague-Dawley rats, intraperitoneal administration of LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg), attenuates ventriculomegaly, and effectively reduces hydrocephalus. The administration of LSKL, an inhibitor of thrombospondin (TSP-1), suppresses TGF-β1 activity and the ensuing Smad2/3 signaling[1]. ?LSKL, or Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, ip), effectively prevents partial hepatectomy-induced activation of the transforming growth factor (TGF) β-Smad signal. Thrombospondin (TSP-1) inhibitor LSKL effectively inhibits TGF-β-Smad signal activation by opposing TSP-1, but not by lowering TSP-1 protein expression. Following a hepatectomy, hepatocyte proliferation is accelerated by LSKL, an inhibitor of thrombospondin (TSP-1)[3].
|
| Animal Protocol |
Animal/Disease Models: 103 male SD (Sprague-Dawley) rats (6 weeks of age; 160-180 g) with subarachnoid hemorrhage (SAH)[1]
Doses: 1 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: Was protective against subarachnoid fibrosis, attenuated ventriculomegaly and effectively suppressed hydrocephalus. |
| References |
[1]. Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31.
[2]. Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61. [3]. Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25. |
| Molecular Formula |
C23H43F3N6O7
|
|---|---|
| Molecular Weight |
572.62
|
| CAS # |
2828433-17-4
|
| Related CAS # |
LSKL, Inhibitor of Thrombospondin (TSP-1);283609-79-0
|
| SMILES |
[C@@H](C(=O)N)(CC(C)C)NC(=O)[C@@H](NC([C@H](CO)NC(=O)[C@@H](N)CC(C)C)=O)CCCCN.OC(=O)C(F)(F)F
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (436.59 mM)
H2O: 100 mg/mL (174.64 mM） |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 100 mg/mL (174.64 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7464 mL | 8.7318 mL | 17.4636 mL | |
| 5 mM | 0.3493 mL | 1.7464 mL | 3.4927 mL | |
| 10 mM | 0.1746 mL | 0.8732 mL | 1.7464 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
